Psyence Biomedical (PBM) Research & Development (2024 - 2025)

Psyence Biomedical (PBM) posted quarterly Research & Development of $357444.0 for Q3 2025, up 34.57% year-over-year from $265626.0 in Q3 2024, and up 34.57% on a QoQ basis from $265626.0 in Q3 2024.

Psyence Biomedical (PBM) Research & Development (2024 - 2025) Analysis & Trends

Psyence Biomedical (PBM) has reported Research & Development for 2 consecutive years, with $357444.0 the latest figure, recorded in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Genmab A 276,399.99 Bn 276,398.47 Bn 831.00 Mn -440.00 Mn
2 Akari Therapeutics 1,217.26 Bn 1,217.26 Bn - 1.46 Mn
3 BeOne Medicines 419.38 Bn 414.59 Bn 1.35 Bn 541.22 Mn
4 Vertex Pharmaceuticals 126.54 Bn 119.30 Bn 2.59 Bn 961.60 Mn
5 Pharming 110.17 Bn 110.12 Bn 65.80 Mn -25.56 Mn
6 Regeneron Pharmaceuticals 64.97 Bn 56.22 Bn 3.31 Bn 1.54 Bn
7 Argenx Se 56.44 Bn 56.44 Bn 1.18 Bn -443.00 Mn
8 Alnylam Pharmaceuticals 40.09 Bn 37.08 Bn 959.66 Mn 364.87 Mn
9 Revolution Medicines 37.15 Bn 37.15 Bn - 343.97 Mn
10 Psyence Biomedical 1.72 Mn 1.72 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 357,444.00
Sep 30, 2024 265,626.00